TransAct Technologies reported preliminary Q3 2026 financial results with net sales of $14.4 million, up 10% year-over-year, driven by a 33% increase in food service technology revenue. The company reported a net loss of $0.44 million and revised its full-year 2026 revenue guidance downward to $55-$56 million due to softening demand in the Casino and Gaming segment.
Term
Q3 2026
“Our food service technology business drove a strong third quarter, with FST revenue up 33% year-over-year with growth across hardware, software and labels. We sold 2,346 BOHA! units in the quarter, and software revenue grew approximately 61% as pricing actions, new account wins and bundled software packages take hold across our installed base.”
John Dillon, Chief Executive Officer of TransAct
“Casino and Gaming softened in the quarter, consistent with the cyclicality that we have seen in the past, and we expect the softer demand environment to continue into the fourth quarter. However, the fundamentals of this business are unchanged.”
For the nine months ended September 30, 2026, Antares Strategic Credit Fund II LLC reported total investment income of $11.0 million and net investment income of $5.3 million. The fund's net asset value per share decreased to $24.76 from $25.28 at the end of 2025, primarily due to net unrealized depreciation on investments and distributions declared.
Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.
Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.
Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”
SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.
Planet 13 Holdings reported a net loss of $20.0 million for the nine months ended September 30, 2026, an improvement from the $59.3 million loss in the prior year period. The company successfully exited all California operations during the quarter and is monitoring the impact of the U.S. Department of Justice's move to reclassify medical marijuana to Schedule III, which may alleviate Section 280E tax burdens.
Heartflow, Inc. reported a total asset base of $355.3 million as of September 30, 2026, with a significant accumulated deficit of $1.14 billion. The company remains focused on its Heartflow FFRCT and Plaque Analysis products while maintaining a liquid position of approximately $167.7 million in cash and short-term investments.
Serina Therapeutics reported a net loss of $21.2 million for the nine months ended September 30, 2026, as it continues to invest in research and development. The company significantly strengthened its balance sheet during the period, increasing cash and cash equivalents to $19.4 million through private placements and equity facilities.
For the nine months ended September 30, 2026, Antares Private Credit Fund reported total investment income of $114.9 million and net investment income of $52.7 million. Net assets increased by $39.5 million from operations, though the fund experienced a net change in unrealized depreciation of $12.0 million during the period.
Once Upon a Farm reported Q3 2026 net sales of $89.1 million, a 35% increase year-over-year driven by 32% volume growth. The company narrowed its net loss to $3.8 million from $11.3 million in the prior year, though Adjusted EBITDA shifted to a $1.0 million loss due to lower gross margins from trade investments and product mix.
Term
Q3 2026
“Third quarter results demonstrated our ability to increase brand awareness and household penetration, deepen and expand retail reach, and deliver value added innovation. As more families consume our products in greater frequency, alongside disciplined investment and execution, we are on course to build the first truly baby through kid brand, with meaningful operating leverage and structurally higher margins as we scale.”
John Foraker, CEO and co-founder of Once Upon a Farm
“We are building one of the most compelling, durable growth platforms in food with increasing household penetration, strong consumer loyalty, attractive retail productivity, and significant opportunities to expand our reach in new categories relevant to our consumers.”
John Foraker, CEO and co-founder of Once Upon a Farm
Sensus Healthcare reported Q3 2026 revenue of $6.0 million, a 13% decrease year-over-year due to a shift in product mix and the absence of sales to a historically large customer. Despite lower revenue, gross margin improved significantly to 55% from 39.1% in the prior year, and the company reached a milestone of 1,000 SRT systems placed.
Term
Q3 2026
“Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability.”
Joseph Sardano, Chairman and Chief Executive Officer
“Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business.”
Joseph Sardano, Chairman and Chief Executive Officer
Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.
Streamex Corp. reported a significant increase in net loss to $78.7 million for the nine months ended September 30, 2026, compared to $38.8 million in the prior year, primarily driven by a surge in general and administrative expenses. The company transitioned its focus toward gold-leasing activities and digital assets, while successfully extinguishing $38 million in convertible debentures during the period.
GrabAGun Digital Holdings Inc. reported a net loss of $6.69 million for the nine months ended September 30, 2026, compared to a loss of $2.92 million in the prior year period, despite a 5.3% increase in net revenues to $70.38 million. The company's cash position decreased to $96.03 million from $110.40 million at year-end 2025, primarily due to increased capital expenditures and stock repurchases.
For the nine months ended September 30, 2026, Remora Capital Corp reported total investment income of $18.0 million and net investment income of $10.9 million. The company's Net Asset Value (NAV) per common share decreased from $9.98 at the end of 2025 to $9.75, primarily driven by $4.6 million in net unrealized depreciation on investments.
Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.
Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.
“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”
Willie Quinn, President and Chief Executive Officer
“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”
Parabilis Medicines, Inc. is a clinical-stage biotechnology company that remains pre-revenue and has incurred significant losses since inception. As of November 9, 2026, the company had approximately 125.3 million total shares outstanding and is focused on advancing its Helicon discovery platform and lead product candidate, zolucatetide.
Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.
BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.
“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
INVE Technologies reported Q3 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year due to the divestiture of its IoT business to Trackonomy. The company achieved GAAP net income of $0.6 million, driven by a gain on the asset sale, but currently has no commercial revenue following the transaction and is not providing future guidance.
Flowers Foods reported a significant increase in cash and cash equivalents to $72.2 million as of October 10, 2026, compared to $12.1 million at the start of the fiscal year. The company is currently executing strategic initiatives including an ERP system upgrade and the acquisition of Simple Mills while managing risks related to independent distributor partner classifications.
4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”
David Kirn, MD, Co-founder, President and Chief Executive Officer
Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.
Term
Q3 2026
“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant
For the nine months ended September 30, 2026, Evommune, Inc. reported a net loss of $84.8 million, more than double the $40.6 million loss in the prior year period, primarily driven by increased research and development and general and administrative expenses. Total assets grew to $278.3 million as of September 30, 2026, supported by cash and investments totaling approximately $262.3 million.
MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.
Term
Q3 2026
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”
Eric Risser, President and Chief Executive Officer
“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”
Eric Risser, President and Chief Executive Officer
Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.
Term
Q3 2026
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Martin Babler, President and Chief Executive Officer of Alumis
Cibus, Inc. reported financial results for the third quarter of 2026, highlighting progress in its rice herbicide-tolerance traits and the initiation of manufacturing for its first two biofragrance products. The company reduced its year-to-date cash usage by 19% year-over-year and expects to exit 2026 with an annualized net cash usage run rate of approximately $35 million.
Term
Q3 2026
“Three months ago I described three ways our platform creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Each of these moved closer this quarter. We received requests from our customer for larger quantities of two biofragrance products to advance their product development. Our Rice traits performed well in Latin American field trials and are now being tested where it counts, in our customer Interoc's own varieties in its own fields. Further, a second partner-funded crop program, Mustard in India, began work in the quarter.”
Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.